Registration number: ЛСР-001431/07
Trade name: Glycine
International non-proprietary name: glycine.
Dosage form: sublingual tablets.
Ingredients per 1 tablet: microcapsulated glycine (expressed as active ingredient glycine – 100 mg), excipients: methylcellulose – 1 mg, magnesium stearate – 1 mg.
Appearance: round flat cylindrical tablets, white to off-white with elements of marbling, beveled and scored.
Therapeutic category: metabolic drug.
ATC code: N06BX.
Glycine is an amino acid and one of the main inhibitory neurotransmitters in the brain. Glycine normalizes and activates the processes of protective inhibition in the central nervous system, reduces psycho-emotional stress, and increases mental efficiency.
Glycine has glycine- and GABAergic effect, alpha1-adrenergic blocking activity; it also regulates the activity of glutamate (NMDA) receptors.
The medicine has the following properties:
- reduces psycho-emotional stress, irritability, proneness to conflict; improves social adaptation;
- improves mood;
- facilitates falling asleep and normalizes sleep;
- increases mental efficiency;
- reduces vegetative-vascular disorders (including those in menopause);
- reduces the severity of cerebral disorders in ischemic stroke and traumatic brain injury;
- reduces the toxic effect of alcohol and other drugs that depress the function of the central nervous system.
Pharmacokinetics: easily penetrates into most biological fluids and body tissues, as well as into the brain; metabolized to water and carbon dioxide; accumulation in the body does not occur.
Indications for use
Indications for use:
- reduced mental efficiency;
- stressful situations – psychoemotional stress (during exams, in conflict situations, etc.);
- deviant forms of behavior in children and adolescents;
- various functional and organic diseases of the nervous system, accompanied by increased excitability, emotional instability, decreased mental efficiency, memory and sleep disorders: neuroses, neurosis-like states and vegetative vascular disorders, stress nervous disorders, the consequences of neuroinfections and traumatic brain injury, perinatal and others forms of encephalopathy (also alcoholic ones);
- ischemic stroke.
Contraindications: hypersensitivity to glycine or to other components of the drug.
Dosage and administration
Precautions for use: does not require special precautions.
Administration of the drug during pregnancy and breastfeeding: we don’t recommend using Glycine during pregnancy and breastfeeding due to the lack of sufficient data.
Dosage and administration: Glycine is applied sublingually or buccally (as a tablet or powder after crushing a tablet): in adults, adolescents and children over 3 years old – 1 tablet (100 mg), children under 3 years old – half of the tablet (50 mg).
Glycine is prescribed to practically healthy children, adolescents and adults in case of: psycho-emotional stress; stressful nervous disorders; decreased memory, mental focus or efficiency; mental retardation; deviant behavior: 2-3 times a day for 14-30 days.
In case of functional and organic lesions of the nervous system, accompanied by increased excitability, emotional instability and sleep disturbance: - for children under 3 years old: 2-3 times a day for 7-14 days, then once a day for 7-10 days, daily dose – 100-150 mg, total dose during medication – 2000-2600 mg; - children over 3 years old, adolescents and adults: 2-3 times a day for 7-14 days, daily dose – 200-300 mg, total dose during medication – 2800-4200 mg.
Duration of treatment can be increased up to 30 days, if recommended by the doctor, the treatment can be repeated after 30 days.
In case of sleep disorders: take in 20 minutes or just before going to sleep, take 0.5-1 tablet (depending on age).
In case of ischemic stroke: during the first 3-6 hours from the development of a stroke, take 1000 mg sublingually or buccally with one teaspoon of water, after that 1000 mg per day for 1-5 days, then 1-2 tablets 3 times a day for the next 30 days.
In addiction treatment glycine is used as an agent that increases mental efficiency and reduces psycho-emotional stress during remission in case of symptoms of encephalopathy, organic lesions of the central and peripheral nervous system: 1 tablet 2-3 times a day for 14-30 days. If necessary, treatment can be repeated 4-6 times a year.
Side effects: allergic reactions (very rare).
Overdose: no cases of overdose have been identified.
Drug interactions: reduces the severity of side effects of antipsychotics (neuroleptics), anxiolytics, antidepressants, hypnotics and anticonvulsants.
Special warnings: in patients with a tendency to arterial hypotension, it is necessary to control blood pressure while taking the drug and, if necessary, the dose must be adjusted. If the pressure drops below the normal level, the treatment should be stopped.
Possible effects on ability to drive vehicles or use potentially dangerous machines does not affect.
Package: sublingual tablets 100 mg. 50 tablets in a blister made of polyvinyl chloride film and aluminum foil. 1 or 2 blister packs together with instructions for use in a cardboard box.
Storage conditions: in original package at a temperature not exceeding 25 С°.
Keep out of the reach of children.
Shelf life: 3 years. Do not use after labeled expiration date.
Prescription status: no prescription required.
Name and address of manufacturer/company which accepts customer complaints: LLC “Medical Scientific and Production Complex “BIOTIKI”. Russia, 115404, Moscow, 6th Radialnaya st., 24, bldg. 1, 2, 14, 15.
Phone: +7 (495) 327-86-30
Toll-free hotline in Russia: 8-800-100-32-22